Former Executive Vice President, Research and Development · Viridian Therapeutics, Inc. (VRDN)

Paul Rubin

A named executive officer of Viridian Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$632,738

Salary $426,000Stock awards $0

FY2018: $976,769

2nd of 4 named executive officers at Viridian Therapeutics by FY2019 total.

4 named officers on file for Viridian Therapeutics, FY2019

Paul Rubin’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • VRDN’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Viridian Therapeutics’s whole pay program stands against its peers

  • Viridian Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VRDN→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 10, 2020 (DEF 14A).

Free

Get Paul Rubin’s full pay file as a PDF — free

More than this page: up to 10 years of Paul’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Paul Rubin compensation by year

Viridian Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Viridian Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018FY2019
Salary$395,000$410,000$426,000
Bonus$142,200$98,400$0
Stock awards$0$0$0
Option awards$704,149$468,369$206,738
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$0$0$0
Total$1,241,349$976,769$632,738

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Viridian Therapeutics, Inc. DEF 14A filed April 10, 2020, accession 0001590750-20-000034, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Viridian Therapeutics, Inc. filed document, accession 0001590750-20-000034. Every figure is read from that document and cited to the page and table it appears in. Filed April 10, 2020.

$1.2M
$977K
$633K
FY17
FY18
FY19
SalaryBonusOption awards

Viridian Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
William MarshallPresident and Chief Executive Officer$1,072,302
Paul Rubin · this pageFormer Executive Vice President, Research and Development$632,738
Diana EscolarChief Medical Officer$543,788
Jason LeveroneChief Financial Officer$533,223

The full Viridian Therapeutics compensation record

free company brief

This page is one person within Viridian Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Viridian Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Viridian Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Paul Rubin's compensation dossier · One-time report. No refunds.